nDatalyze (NDAT) Stock Overview

Provides technologically based solutions related to applying machine learning to a records database to predict probable mental health conditions. More details

NDAT fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings have grown 16.2% per year over the past 5 years

Risk Analysis

Does not have a meaningful market cap (CA$4M)

Highly volatile share price over the past 3 months compared to the Canadian market

Makes less than USD$1m in revenue (CA$0)

NDAT Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

nDatalyze Corp. Competitors

Price History & Performance

Summary of share price highs, lows and changes for nDatalyze
Historical stock prices
Current Share Price	CA$0.065
52 Week High	CA$0.20
52 Week Low	CA$0.015
Beta	0.15
1 Month Change	-27.78%
3 Month Change	225.00%
1 Year Change	225.00%
3 Year Change	8.33%
5 Year Change	-65.79%
Change since IPO	-7.14%

Recent updates

Analysis Article • Jan 14

Is MedXtractor Corp.'s (CSE:MXT) 1.1% ROE Worse Than Average?

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

Shareholder Returns

	NDAT	CA Healthcare Services	CA Market
7D	-35.0%	2.4%	1.0%
1Y	225.0%	-11.6%	34.0%

Return vs Industry: NDAT exceeded the Canadian Healthcare Services industry which returned -13.8% over the past year.

Return vs Market: NDAT exceeded the Canadian Market which returned 34.5% over the past year.

Price Volatility

Is NDAT's price volatile compared to industry and market?
NDAT volatility
NDAT Average Weekly Movement	83.0%
Healthcare Services Industry Average Movement	11.4%
Market Average Movement	10.3%
10% most volatile stocks in CA Market	17.8%
10% least volatile stocks in CA Market	4.0%

Stable Share Price: NDAT's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: Insufficient data to determine NDAT's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2018	n/a	Jim Durward	www.ndatalyze.com

nDatalyze Corp. provides technologically based solutions related to applying machine learning to a records database to predict probable mental health conditions. It offers Sigmund, a machine-learning-based online mental health application for the mental health system, such as misdiagnosis and mis prescription. The company was formerly known as MedXtractor Corp. and changed its name to nDatalyze Corp. in October 2021.

nDatalyze Corp. Fundamentals Summary

How do nDatalyze's earnings and revenue compare to its market cap?
NDAT fundamental statistics
Market cap	CA$3.72m
Earnings (TTM)	-CA$304.39k
Revenue (TTM)	n/a

0.0x

P/S Ratio

-8.8x

P/E Ratio

Is NDAT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NDAT income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$304.39k
Earnings	-CA$304.39k

Last Reported Earnings

Nov 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0074
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did NDAT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/07 05:02
End of Day Share Price	2026/05/07 00:00
Earnings	2025/11/30
Annual Earnings	2025/02/28

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

nDatalyze Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

nDatalyze (NDAT) Stock Overview

Rewards

Risk Analysis

nDatalyze Corp. Competitors

DIAGNOS

Avricore Health

KDA Group

Reliq Health Technologies

Price History & Performance

Recent News & Updates

PRISM Diversified Ltd. entered into a non-binding memorandum of understanding to acquire nDatalyze Corp. (CNSX:NDAT) in a reverse merger transaction.

nDatalyze Corp., Annual General Meeting, Apr 15, 2026

Insufficient new directors

An undisclosed buyer entered into a Binding Memorandum of Understanding to acquire nDatalyze Corp. (CNSX:NDAT) in a reverse merger transaction.

Ameresco Holding LLC cancelled the acquisition of nDatalyze Corp. (CNSX:NDAT) in a reverse merger transaction.

Insufficient new directors

Recent updates

PRISM Diversified Ltd. entered into a non-binding memorandum of understanding to acquire nDatalyze Corp. (CNSX:NDAT) in a reverse merger transaction.

nDatalyze Corp., Annual General Meeting, Apr 15, 2026

Insufficient new directors

An undisclosed buyer entered into a Binding Memorandum of Understanding to acquire nDatalyze Corp. (CNSX:NDAT) in a reverse merger transaction.

Ameresco Holding LLC cancelled the acquisition of nDatalyze Corp. (CNSX:NDAT) in a reverse merger transaction.

Insufficient new directors

New major risk - Financial position

Second quarter 2025 earnings released: CA$0.005 loss per share (vs CA$0.004 profit in 2Q 2024)

nDatalyze Corp. Announces Positive Clinical Study Results, and Mindbalanced Update

New minor risk - Share price stability

nDatalyze Corp. Announces Change in President

Full year 2024 earnings released: CA$0.004 loss per share (vs CA$0.032 loss in FY 2023)

nDatalyze Corp. Announces Clinical Study Update

nDatalyze Corp. Updates the Clinical Study

nDatalyze Corp. announced that it has received CAD 0.20625 million in funding

nDatalyze Corp. announced that it expects to receive CAD 0.20625 million in funding

Ndatalyze Corp. Announces Executive Changes

nDatalyze Corp. (CNSX:NDAT) completed the acquisition of Mindbalanced Inc.

New minor risk - Share price stability

nDatalyze Corp., Annual General Meeting, Mar 14, 2024

Third quarter 2024 earnings released: CA$0.004 loss per share (vs CA$0.006 loss in 3Q 2023)

Insufficient new directors

New minor risk - Shareholder dilution

nDatalyze Corp. announced that it has received CAD 0.2778 million in funding

nDatalyze Corp. Announces Appointment of Dr. Keith Courtney as President and Chief Psychiatric Officer

Second quarter 2024 earnings released: EPS: CA$0.004 (vs CA$0.006 loss in 2Q 2023)

nDatalyze Corp. Advances Its Clinical Study Process

nDatalyze Corp. Begins a Clinical Study Process

Full year 2023 earnings released: CA$0.032 loss per share (vs CA$0.032 loss in FY 2022)

Third quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.001 loss in 3Q 2022)

nDatalyze Corp. Anticipates YMI ChatGPT Testing

nDatalyze Corp. Announces Two Video Initiatives to Augment Its Phase 2 Marketing Program

nDatalyze Corp. Announces Canada-Wide Release of YMI

Second quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.003 loss in 2Q 2022)

nDatalyze Corp., Annual General Meeting, Nov 30, 2022

First quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.002 loss in 1Q 2022)

Full year 2022 earnings released: CA$0.032 loss per share (vs CA$0.027 loss in FY 2021)

nDatalyze Announces YMI mHealth Application Beta is Now Online

nDatalyze Corp. announced that it expects to receive CAD 1.25 million in funding

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

nDatalyze Announces Successful Proof-Of-Concept and Progress Update

Second quarter 2022 earnings released: CA$0.003 loss per share (vs CA$0.001 profit in 2Q 2021)

First quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.001 profit in 1Q 2021)

Medxtractor Corp Updates Reference Record Collection Progress

Full year 2021 earnings released: CA$0.027 loss per share (vs CA$0.002 loss in FY 2020)

MedXtractor Corp. announced that it has received CAD 1.815 million in funding

President exercised options and sold CA$78k worth of stock

Chief Financial Officer recently sold CA$99k worth of stock

New 90-day high: CA$0.27

MedXtractor Corp. announced that it expects to receive CAD 1.6 million in funding

Medxtractor Corp. Updates the SHAMAN Psychedelics Artificial Intelligence Project

New 90-day high: CA$0.24

New 90-day high: CA$0.21

Is MedXtractor Corp.'s (CSE:MXT) 1.1% ROE Worse Than Average?

Medxtractor Corp. Announces Commencement of "SHAMAN"

Third quarter 2021 earnings released: CA$0.001 loss per share

MedXtractor Corp. Announces Board Changes

Shareholder Returns

Price Volatility

About the Company

nDatalyze Corp. Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status